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Usefulness of contrast-enhanced computed tomography
for diagnosing hepatic steatosis
Thipsumon Tangsiwonga, b, Thitinan Chulroekb, *
Department of Radiology, Buddhachinaraj Phitsanulok Hospital, Phitsanulok 65000, Thailand
Department of Radiology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn
Memorial Hospital, Bangkok, Thailand
a
b

Background: The diagnosis of hepatic steatosis has been well-described on unenhanced computed
tomography (UECT) study. However, current UECT often discarded from the abdominal CT protocol due to
radiation dose reduction.
Objective: To determine accuracy of contrast-enhanced CT (CECT) for diagnosis of hepatic steatosis.
Methods: A total of 1,001 patients who underwent unenhanced and portal venous phase abdominal CT studies
were assessed by using region-of-interests of liver and spleen, and visual detection of focal fat sparing. UECT
diagnostic criteria were used as the standard reference.
Results: The optimal cut-offs on CECT images were 110 Hounsfield unit (HU) of liver attenuation and -20 HU
of liver-splenic differential (L-S) attenuation. Sensitivity, specificity, accuracy and receiver operating
characteristic curve areas for quantitative liver attenuation values were 90.4%, 73.6%, 75.9% and 0.926, respectively;
and for L-S attenuation values were 83.1%, 70.8%, 72.5% and 0.856, respectively. Qualitatively, geographic fat
sparing was 100.0% specificity; however, its sensitivity (50.7%) was rather low.
Conclusion: Portal venous phase CECT can be used for detection of hepatic steatosis in abdominal CECT
study without the preceding unenhanced phase.
Keywords: Hepatic steatosis, fatty liver, contrast-enhanced computed tomography, focal fat sparing.

Hepatic steatosis or fatty liver disease has
become a common health problem with an estimated
prevalence of 10.0 – 58.0% in the general population.(1)
It is a reversible condition that can progress to
steatohepatitis and eventually cirrhosis in some
patients. (1) Superimposed hepatic steatosis has
an effect on disease progression and treatment
response in viral hepatitis patients as well as that
related to worsened recipient prognosis after liver
transplantation.(2)
Liver biopsy with histologic analysis is a gold
standard for assessment of hepatic steatosis.
However, because of the invasiveness, the use of this
procedure potentially declines and is replaced by
cross-sectional imaging techniques included
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ultrasonography (US), computed tomography (CT)
and magnetic resonance imaging (MRI) which are
non-invasive, cost-effectiveness and high accurate in
the detection of the steatotic liver.(3 - 5) Ultrasound is
the first imaging modality due to its availability and
low-cost technique, but its use is somewhat limited
due to qualitative assessment, unable to detection
of low level of steatosis and inaccuracy in obese
patients.(3) CT and MRI provide better accuracy and
good reproducibility; however, CT is less expensive
and is more widely used than MRI.(3)
Unenhanced CT (UECT) that is a simplified and
non-invasive diagnostic method has widely been
used to evaluate hepatic steatosis without the need
for liver biopsy proven. Whereas contrast-enhanced
CT (CECT) is still a questionable role and tends
to be less useful. (4) Although the prior studies
proposed about diagnostic criteria that had quite high
accuracy, none of them was used in routine clinical
practice.(1, 4 - 5)
To date, many abdominal CECT studies are
potentially performed without the preceding UECT
to avoid unnecessary radiation exposure. Meanwhile,
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the CECT diagnostic criteria of hepatic steatosis are
inconclusive. Therefore, the purpose of this study was
to determine accuracy of the optimal cut-off on CECT
for detecting hepatic steatosis and to analyze CT
factors that might affect the accuracy.
Materials and methods
The retrospective analysis was based on patient
data searching from the picture archiving and
communication system (PACS) at our hospital. A
total of 2,483 consecutive patients who underwent
unenhanced and portal venous phase CECT of the
upper abdomen on the same day between January
2014 and August 2014 were enrolled. The patients
who had the following criteria were excluded: liver
cirrhosis, acute hepatic injury, numerous hepatic
space-taking lesions, liver attenuation on UECT
reached 75 Hounsfield unit (HU),(6) previous right
hepatectomy, biliary ductal dilation, asplenia or
splenectomy, presence of artifacts related to metallic
materials or motion, presence of more than trace
ascites and incomplete patient information. A
final 1,001 patients were recruited in our study. The
Institutional Review Board’s approval was obtained
for the retrospective study. The informed consent of
the subject was waived.
All patients were performed at least UECT and
portal venous-phase CECT images of the upper
abdomen by using a 64-multidetector CT scanner
(Discovery CT750 HD; GE healthcare, UK) after
6-hour fasting with the following parameters: beam
collimation, 64 x 0.625 mm; beam pitch, 1.375; gantry
rotation time, 0.5 sec; 120 kVp; the maximum
allowable tube current set at 200 mAs on an automated
dose reduction system (Auto or Smart mA, GE
Healthcare); field of view to fit.
Depending on the patients’ sizes and CT protocols,
estimated volume of contrast administration was
individually used about 2 mL/kg in most of abdominal
CT protocols, not exceeding 100 - 120 mL/dose; and
2 - 3 mL/kg in pancreatic protocol or CT angiography
because of higher injection rate, not exceeding
120 - 150 mL/dose. Therefore, a bolus of 100 to
120 mL of Iopromide (Ultravist 300; Bayer Schering
Pharma AG, Berlin, Germany) or Iohexol (Omnipaque
350; GE Healthcare) was intravenously injected
at a rate of 1.2 to 4.0 mL/s through 20 or 22-gauge
angiographic catheter inserted into an antecubital
vein in each patient. Portal venous-phase images
were obtained in the range of 70 to 100 seconds after
the initiation of intravenous contrast administration.
Axial images with 2.5-mm slice thickness were
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reconstructed for both UECT and portal venous-phase
CECT images.
For each individual, liver and splenic attenuations
were measured in HU by averaging two 1.0  0.1cm2 circular region-of-interests (ROIs) placed above
and below the main portal vein plane in both UECT
and CECT images on the same/resemble slices
by illustrating vascular anatomy. To prevent partialvolume averaging effect, special care was taken to
avoid measurements of vessels, focal lesions, areas
of artifact and the edge of organ. Furthermore, the
posterior half of right hepatic lobe was only assessed
due to similar anatomic location and artifacts between
the liver and spleen (Figure 1). For each CT-phase
image, ROIs of the liver and splenic measurements
were calculated separately in mean attenuation
values. Liver-splenic differential (L-S) attenuation
were then computed.
Typical characteristics of focal fat sparing
including a geographic area of relatively increased
attenuation in the liver, locations in specific areas (e.g.
adjacent to falciform ligament, ligamentum venosum,
porta hepatis and gallbladder fossa) and absence of a
mass effect on vessels and other liver structures(1, 7)
(Figure 2) on CECT images were recorded.
Either the liver attenuation on UECT image of
less than or equal to 40 HU(7) or L-S attenuation less
than or equal to -10 HU(8) was used as the reference
standard for diagnosis of moderate to severe hepatic
steatosis. Biopsy proof was omitted.
All drawn ROIs and identified focal fat sparing
were performed by a 3rd-year radiology resident (T.T.)
on a PACS system (Synapse, Fuji Medical Systems)
by using standard adjustable abdominal window width
and level settings. In order to analyze interobserver
agreement, 52 patients were randomly selected, and
the ROI measurements and focal fat sparing detection
were redone by a board-certificated radiologist (T.C.
with over 3 years of experience in abdominal imaging)
who did not know the initial results.
Statistical analysis
Statistical analysis was performed using
SPSS 17.0 for Windows (SPSS, Chicago, IL).
Normally distributed continuous data are presented
as mean  standard deviation (SD), 95% confidence
interval (CI). Non-parametric data are presented as
numbers of cases and percentages. Comparing
hepatic attenuation and L-S attenuation between
steatotic and non-steatotic groups were analyzed by
unpaired Student’s t - test.
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Figure 1. Attenuation measurements of liver and spleen on UECT (left) and portal venous-phase CECT (right) in two
levels. Four liver ROIs were drawn above and below plane of portal vein bifurcation avoiding vessels, bile
ducts, focal lesions and liver edge. Two splenic ROIs were drawn in the same manner and CT slice. 91 x 64 mm
(300 x 300 DPI).

Figure 2. Presence of focal fat sparing in the liver on CECT images. (A): A geographic fat sparing was detected nearby
gallbladder fossa (arrow). (B): Focal fat sparing located adjacent to ligamentum venosum and along
subcapsular region of hepatic segment III (arrowhead). Aortic dissection and hepatic cyst were noted.
118 x 46 mm (300 x 300 DPI)

The optimal threshold for diagnosis of hepatic
steatosis on CECT was determined by Receiver
Operator Characteristic (ROC) curve and calculated
sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV) and accuracy over
a range of possible liver attenuation diagnostic
threshold, L-S attenuation diagnostic threshold or
combined. The maximum overall accuracy value
was chosen. Presence of focal fat sparing was also
evaluated efficacy by calculating sensitivity, specificity,
PPV, NPV and accuracy.
The effect of delayed CT scan time, rate of
contrast injection, volume and concentration of contrast
media on the liver and splenic enhancements
(the attenuation differences between CECT and
UECT images) was analyzed by Pearson correlation.

Interobserver agreement was determined by using
paired t - test and Cohen’s Kappa (κ) statistics. The
scale of the Cohen’s Kappa used for interpretation of
weighted k statistics was: slight agreement 0 - 0.20;
fair agreement 0.21 - 0.40; moderate agreement
0.41 - 0.60; substantial agreement 0.61 - 0.80; and
almost perfect agreement 0.81 - 1.00. P - value
< 0.05 was considered to be a statistical significance.
Results
A total of 1,001 patients (mean age, 58.1 years;
range, 18 - 90 years), including 419 males (mean age,
59.9 years; range, 21 - 88 years) and 582 females
(mean age, 56.8 years; range, 18 - 90 years),
constituted the study population. The clinical
indications for the examinations were mainly
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abdominal pain (29.0%) and patients with cancers as
follows: colorectal cancer (24.0%), breast cancer
(8.5%), gastrointestinal stromal tumor (5.4%),
lymphoma (4.7%), lung cancer (3.3%) and pancreatic
cancer (3.3%).
Using the UECT diagnostic criteria, 136 (13.6%)
of 1,001 patients had hepatic steatosis (mean age,
56.9 ± 11.8 years). Of these, 44.1% were male. The
values of the liver and L-S attenuation on both UECT
and CECT images as well as the presence of focal
fat sparing are displayed in Table 1.
For the diagnosis of hepatic steatosis on CECT,
the area under curves (AUCs) of the liver and L-S
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attenuations were calculated about 0.926 [95% CI,
0.900 – 0.952] and 0.856 [95% CI, 0.824 - 0.888],
respectively (Figure 3). The optimal cut-offs of the
liver and L-S attenuations which were the upper
limit to diagnose hepatic steatosis were summarized
along with corresponding sensitivity, specificity, PPV,
NPV and accuracy. The cut-offs were 110 HU for
liver attenuation and -20 HU for L-S attenuation, using
as the diagnostic criteria. The sensitivity, specificity,
PPV, and accuracy of the such criteria are described
in Table 2.

Table 1. Attenuation values and presence of focal fat sparing.

UECT (Mean ± SD; HU)
Liver attenuation
L-S attenuation
CECT (Mean ± SD; HU)
Liver attenuation
L-S attenuation
Focal fat sparing (%)

With steatosis

Without steatosis

P - value

30.8 (± 11.3)
- 17.5 (± 11.4)

57.9 (± 6.5)
8.3 (± 6.4)

< 0.001*
< 0.001*

82.8 (± 21.6)
- 43.9 (± 23.9)
69 (50.7)

122.0 (± 17.8)
- 12.6 (± 18.0)
0 (0)

< 0.001*
< 0.001*
< 0.001*

SD = standard deviation, HU = Hounsfield unit.
*P - value less than 0.05 was statistically significant.

Post-contrast CT
Liver attenuation
L-S attenuation
1.0

Sensitivity

0.8

0.6

0.4

0.2

0.0

0.0

0.2

0.4

0.6

0.8

1.0

1 - Specificity

Diagonal segments are produced by ties
Figure 3. The ROC curve showed the diagnostic performance of liver and L-S attenuations on CECT for the diagnosis
of hepatic steatosis. 78 x 85 mm (300 x 300 DPI)
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Table 2. Diagnostic performance of the attenuation values on contrast-enhanced CT for diagnosing hepatic steatosis.

Cut-off value*
Sensitivity**
Specificity**
PPV**
NPV**
Accuracy**

Value
95% CI
Value
95% CI
Value
95% CI
Value
95% CI
Value

Liver attenuation

L-S attenuation

Combination of two criteria

110
90.4 (123/136)
83.9 - 94.6
73.6 (637/865)
70.5 - 76.5
35.0 (123/351)
32.1 - 38.1
98.0 (637/650)
96.5 - 98.9
75.9 (760/1001)

-20
83.1 (113/136)
75.5 - 88.7
70.8 (613/865)
75.5 - 88.8
30.9 (113/365)
26.3 - 36.0
96.4 (613/636)
94.5 - 97.6
72.5 (726/1001)

77.2 (105/136)
69.1 - 83.8
88.2 (613/865)
85.8 - 90.2
50.7 (105/207)
43.7 - 57.7
96.1 (763/794)
94.4 - 97.3
86.7 (868/1001)

*Values less than or equal to the cutoff value (HU) indicate a positive diagnosis of fatty liver.
**Data are presented as percentages. Data in parentheses are the number of subjects used to calculate the percentage.

Sixty-nine (50.7%) of the 136 steatotic patients
had focal fat sparing; none of the finding was detected
in non-steatotic patients. The sensitivity, specificity,
PPV, NPV and accuracy of the presence of focal fat
sparing were 50.7%, 100.0%, 100.0%, 92.8% and
93.3%, respectively.
Only the delayed scan time showed mild negative
correlation with splenic enhancement (r = - 0.207,
P < 0.001), whereas the injected rate, volume and
concentration of contrast media did not. Regarding
the liver enhancement, liver and splenic attenuations,
and L-S attenuation, they each had no correlation with

delayed CT scan time and all parameters of contrast
administration (Table 3).
The subjects for analyzing interobserver
agreement consisted of 18 males (mean age, 59.9
years) and 34 females (mean age, 58.9 years). The
measurement values between two readers showed
no significant difference of all quantitative parameters.
There was substantial agreement in detection of focal
fat sparing between the two readers (κ = 0.729; [95%
CI, 0.571-0.835], P < 0.001). The diagnosis of hepatic
steatosis had 100.0% interobserver agreement.

Table 3. Correlation of each parenachymal enhancement with CT scan time and parameters of contrast administration.

Liver enhancement
Splenic enhancement
Liver attenuation
Splenic attenuation
L-S attenuation

Delayed CT
scan time

Contrast administration
Injection rate
Volume

Concentration

r = 0.007
P = 0.819
r = - 0.207
P < 0.001*
r = - 0.011
P = 0.738
r = - 0.192
P < 0.001*
r = 0.179
P < 0.001*

r = 0.104
P = 0.001*
r = - 0.162
P < 0.001*
r = 0.042
P = 0.188
r = - 0.155
P < 0.001*
r = 0.197
P < 0.001*

r = 0.060
P = 0.059
r = 0.039
P = 0.215
r = 0.024
P = 0.439
r = 0.041
P = 0.195
r = - 0.015
P = 0.637

r = correlation coefficient, P = P - value
*P - value less than 0.05 was statistically significant

r = 0.043
P = 0.171
r = 0.063
P = 0.045*
r = - 0.021
P = 0.514
r = 0.052
P = 0.097
r = - 0.074
P = 0.020*
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Discussion
The UECT has traditionally been utilized for
the non-invasive diagnosis of moderate to severe
hepatic steatosis with high specificity without the
need for biopsy proven. Several prior studies have
confirmed that the UECT had high accuracy and
reliability. (5, 8 – 11) In our study, the diagnostic criteria
on the UECT was defined as liver attenuation less
than or equal to 40 HU or L-S attenuation of 10 HU,
at the least.(7, 9)
Recently, many abdominal CT studies are
potentially omitted UECT for radiation reduction.
As a result, the assessment of hepatic steatosis might
be affected. Previous literatures have proposed new
diagnostic criteria of hepatic steatosis on CECT images
with variable indices and accuracies.(1, 4, 7 – 9, 12 – 15)
In our study, we reevaluated portal venous-phase
CECT criteria in the diagnosis of hepatic steatosis,
showing high accurate diagnosis when quantitative
measurement including the liver attenuation or
L-S attenuation was used. Although some prior
authors were interested and studied the L-S
attenuation as a parameter for prediction of the
hepatic steatosis, (4, 8, 12) our study, surprisingly,
demonstrated that the accuracy of liver attenuation
alone was higher than that of L-S attenuation.
Furthermore, we found that the liver attenuation
discriminatory threshold of 110 HU which had a
sensitivity of 90.4%, a specificity of 73.6% and an
accuracy of 75.9% was loose agreement with the
previously reported. (4, 13) Monjardim RF, et al.(13) have
reported that a 104-HU cut-off extended from the
formula of Kim DY, et al.(4) was utilized as a diagnostic
criterion with 100.0% sensitivity and 36.0% specificity,
revealing higher sensitivity but less specificity than
our results. These differences might be a strong
influence of the selection bias towards patients with
mild degree of steatosis from the lesser threshold of
the standard reference in the Monjardim’s study. (13)
The L-S attenuation discriminatory threshold of - 20
HU also had high sensitivity, specificity and accuracy,
being similar to the previous studies. (4, 12) Jacob JE,
et al.(12) have described that the L-S attenuation of 20.5 HU afforded the highest overall diagnostic
sensitivity and specificity when CECT was obtained
delayed scan time at 80 - 100 sec. The delayed
scan time in Jacob’s study (11) and our study
were overlapped and seem to be a similar range. Kim
DY, et al.(4) have found that an optimal threshold for
diagnosing 30.0% hepatic stenosis might be the L-S
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attenuation of - 19 HU with 69.2% sensitivity and
95.8% specificity. Additionally, we created a further
method using a combination of the two diagnostic
criteria which became the most specificity rate than
each criterion separately did. Despite having higher
accuracy, the combined criteria affected a substantial
decrease in sensitivity. Therefore, we supposed to
discuss the usefulness of the CECT criteria into 2
clinical scenarios depending on treatment planning.
Firstly, we need to initiate non-invasive treatment such
as lifestyle modification as soon as possible in this
setting, a higher-sensitivity criterion by using the liver
attenuation or L-S attenuation threshold might be
practical. While, if we would realize a need for liver
biopsy, the most-specificity, combined criteria should
be chosen to avoid an unnecessary tissue proven.
Discovery of focal fat sparing on CECT could be
useful for the diagnosis of hepatic steatosis with 50.7%
sensitivity and 100.0% specificity, similar to the
previous publish.(1) Lawrence DA, et al.(1) have shown
62.0% sensitivity and 100.0% specificity by using focal
fat sparing.
In several studies,(8, 12, 14) the liver and splenic
enhancements on the CECT were mainly affected
by concentration of the contrast medium including
volume, rate and timing of administration, and
circulation. Johnston RJ, et al. (14) have established
that contrast injection rate and CT scan time
significantly influenced on the optimal L-S threshold
and limited the clinical usefulness as well. The
publication of Johnston RJ, et al.(14) was supported
by subsequent studies.(8, 12) Our study, in contrast to
the others,(8, 12, 14) demonstrated that the contrast
concentration and delayed scan time almost had no
influence on parenchymal measurements except that
the splenic enhancement had low inverse correlation
with the delayed scan time (r = - 0.207, P < 0.001).
In clinical practice, all CT scan parameters are
individually adjusted for providing truly portal venous
phase, achieving good image quality and optimizing
radiation dose, therefore, the effects of contrast
concentration and imaging delayed time appear to be
less influential as they are generally determined by
the previous authors. (4, 8, 12, 14)
Our study had some limitations, however. First,
the retrospective design could lead to confounding
bias. In order to avoid such bias, the large sample
size was applied. Second, pathologic confirmation was
omitted; previous literatures have confirmed that
UECT had high accuracy and reliability for the
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diagnosis in routine clinical practice. (1, 6, 8 - 11) Third,
conditions related to hepatic iron deposition and
hyperemia which can cause an increase of hepatic
attenuation(16) and apparently focal fat sparing(1) were
not considered. Finally, several uncontrolled factors
such as habitus, body mass index, cardiac output
and underlying disease(1) might influence on the
parenchymal enhancement.
Conclusion
We concluded that both quantitative and
qualitative assessments on CECT were simple,
non-invasive and highly accurate for diagnosing
moderate to severe hepatic steatosis. Thus, portal
venous-phase CECT might be an alternative
application in detection of the steatotic liver.
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